A2-Iso5-2DC18

• CAT Number: I042746
• CAS Number: 2412492-07-8
• Molecular Formula: C47H87N3O2
• Molecular Weight: 726.21
• Purity: ≥95%
• Synonyms: ethyl 5,5-bis[(Z)-heptadec-8-enyl]-1-(3-pyrrolidin-1-ylpropyl)-2H-imidazole-2-carboxylate
• InChI: InChI=1S/C47H87N3O2/c1-4-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38-47(39-34-32-30-28-26-24-22-20-18-16-14-12-10-8-5-2)44-48-45(46(51)52-6-3)50(47)43-37-42-49-40-35-36-41-49/h19-22,44-45H,4-18,23-43H2,1-3H3/b21-19-,22-20-
• InChIKey: WMYPEEPUVOTFJU-WRBBJXAJSA-N
• SMILES: CCCCCCCCC=CCCCCCCCC1(C=NC(N1CCCN2CCCC2)C(=O)OCC)CCCCCCCC=CCCCCCCCC

A2-Iso5-2DC18 is a dihydroimidazole-linked lipid, served as potent mRNA delivery vehicle. A2-Iso5-2DC18 can be used for antitumor research, including B16F10 melanoma.[1].
A2-Iso5-2DC18, loaded with mLuc or Cre-recombinase mRNA LNPs (mCre), (0.1 mg/kg and 0.5 mg/kg; s.c.; once a week, for 2 weeks) transfects central antigen presenting cells (APCs) in A14/Cre mRNA mouse model[1].
A2-Iso5-2DC18 loaded with OVA mRNA (mOVA) vaccine, (15 μg mOVA per mouse; s.c.; twice dose, once every 5 d) induces a significantly high antigen-specific cytotoxic T lymphocyte (CTL) response, in parallel with robust IFN-ɤ secretion in B16F10 mouse melanoma model[1].

Reference

[1]. Miao L, et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat Biotechnol. 2019 Oct;37(10):1174-1185.
 [Content Brief]